Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.50 |
| ▸ | PKLR | P30613 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591022 | 0.76 | PKM (0.52) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL532887 | 0.74 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL4139118 | 0.74 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL795356 | 0.74 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL677588 | 0.74 | CA1 (0.52) | PKMPKLRPTGES2 | |
| SCHEMBL3926685 | 0.72 | PKM (0.48) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL3926679 | 0.72 | PKM (0.48) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL1299168 | 0.72 | KAT6A (0.46) | NFE2L2 | |
| SCHEMBL12727293 | 0.70 | PKM (0.47) | PKMPKLRCES2CES1KEAP1 | |
| SCHEMBL2021516 | 0.69 | PKM (0.44) | PKMPKLRCES2CES1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0413224-A1 | Fungicidal agent containing 1,2-naphthoquinones | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | PKM 4471/4885PKLR 1705/4885CES2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.